<https://rdf.molmedb.upol.cz/reference/ref4143> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane19>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acsmedchemlett.0c00155"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM494238>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method30>;
	<http://purl.org/dc/terms/bibliographicCitation> "Wilson JE, Patel G, Patel C, Brucelle F, Huhn A, Gardberg AS, Poy F, Cantone N, Bommi-Reddy A, Sims RJ, Cummings RT, Levell JR.: Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor. ACS Med Chem Lett, Volume 11 (6), 2020"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM494237>;
	<http://purl.org/ontology/bibo/pmid> "32551019"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1018501> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4143> .
<https://rdf.molmedb.upol.cz/interaction/int1018500> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4143> .